Investor Profile: APIDC Venture Capital - Thesis, Cheque Size & How to Apply

APIDC Venture Capital is one of India's earliest state-backed venture capital experiments. Set up as a joint venture between the Andhra Pradesh Industrial Development Corporation and privately owned Ventureast, with Ventureast holding 51 per cent and controlling management, it showed how public money could seed private risk capital for science-led businesses. Ventureast describes the APIDC Venture Capital Fund as its first fund.

Investment thesis

The firm's defining bet was biotechnology. In May 2003 it launched India's first dedicated Biotechnology Venture Fund in Hyderabad, aimed at start-up and early-stage companies in healthcare, drug discovery, agriculture, dairy, environmental and industrial applications. Managing director Sarath Naru argued that future drug discoveries and plant technologies would be born in small start-up companies that existing Indian venture funds were not keen to support at early stage. The fund planned to back 20 to 25 ventures in its first three to four years, then begin divesting, with a 10-year fund term.

Fund size and cheque size

The Biotechnology Venture Fund launched with a target of Rs 150 crore. At launch it had raised Rs 35 crore: Rs 15 crore from the Andhra Pradesh government, Rs 10 crore from Andhra Bank and Rs 10 crore committed by the Life Insurance Corporation of India. The International Finance Corporation later committed $4 million, and the fund's target size was reported as $35 million. Typical investments were $1 million to $1.5 million per company, normally up to 15 per cent of a venture's total project cost. No final close size beyond the Rs 150 crore target is publicly documented, so treat that figure as the stated target, not a confirmed total raised.

Notable portfolio

The first three companies sanctioned funding at launch were Genomic Design Pharmaceuticals (Rs 1.5 crore), Bioserve Biotechnology India (Rs 1 crore) and Silico Insight Biosciences (Rs 1.5 crore), all Indo-US projects in biotech research and development. At launch the fund had finalised 14 projects involving Rs 456 crore of project value as suitable for funding. The wider APIDC-VCL portfolio then numbered 18 companies, backed by investors including the World Bank, IDBI, SIDBI and Indian Overseas Bank.

People and programmes

Sarath Naru led APIDC Venture Capital as managing director, and S. M. Balasubramaniam chaired the company at the biotech fund's launch. The programme legacy is the Biotechnology Venture Fund itself, India's first life-sciences venture fund, followed by the Ventureast Tenet Fund, a partnership with the Tenet Group of IIT Madras. No credits or perks programme for founders is documented in the public sources reviewed.

How to apply for funding

Founders should note the current status honestly: APIDC Venture Capital remains a legally active company, but no new APIDC-branded fund is currently marketed in public sources, so there is no verified open application route under the APIDC name today. The live route in this lineage is Ventureast, which describes itself as into its fourth generation of funds with close to $325 million under management. Founders with early-stage technology, healthcare, life-sciences or cleantech businesses can approach Ventureast through its published contact details at ventureast.net, confirming which current fund is open before pitching.